System and method for early detection of Alzheimers by detecting amyloid-beta using orbital angular momentum

• US 10,197,554 B2
• Filed: 10/10/2017
• Issued: 02/05/2019
• Est. Priority Date: 03/12/2014
• Status: Active Grant

• Current Assignee: Nxgen Partners Ip, LLC (NxGen Partners LLC)
• Original Assignee: Nxgen Partners Ip, LLC (NxGen Partners LLC)
• Inventors: Ashrafi, Solyman, Linquist, Roger
• Primary Examiner(s): Stafira, Michael P
• Application Number:
  US15/729,087
• Publication Number:
  US 20180031538A1
• Time in Patent Office: 483 Days
• CPC Class Codes: G01N 2333/4709 Amyloid plaque core protein
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/487 of liquid biological material
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

An apparatus for measuring a concentration of amyloid-beta within a chiral solution includes signal generation circuitry for generating a first signal having an applied first orbital angular momentum signature and applying the first signal to the chiral solution. A detector for receiving the first signal after the first signal passes through the chiral solution and determining the concentration of amyloid-beta within the chiral solution based on a detected second orbital angular momentum signature received from the chiral solution that comprises an amplitude measurement and a phase measurement.

Claims

1. An apparatus for measuring a concentration of amyloid-beta within a chiral solution, comprising:

signal generation circuitry for generating a first signal having an applied first orbital angular momentum signature and applying the first signal to the chiral solution; and

a detector for receiving the first signal after the first signal passes through the chiral solution and determining the concentration of amyloid-beta within the chiral solution based on a detected second orbital angular momentum signature caused by the chiral solution, wherein the detected second orbital angular momentum signature comprises an amplitude measurement and a phase measurement.

2. The apparatus of claim 1, wherein the detector negates effects of at least one of sample distribution due to gravity within the chiral solution, angle of camera recording a mode intensity to the chiral solution, a container holding the chiral solution, an angle of incidence of the first signal to the chiral solution and an angle exit of the first signal from the chiral solution to detect the second orbital angular momentum signature.

3. The apparatus of claim 1, wherein the chiral solution is located in an eye of a patient.

4. The apparatus of claim 1, wherein the signal generation circuitry further comprises:

an emitting source for emitting the first signal comprising a plurality of plane waves; and

orbital angular momentum generation circuitry for receiving the first signal and applying the first orbital angular momentum signature to the first signal to provide an orbital angular momentum twisted signal.

5. The apparatus of claim 1, wherein the detector further includes circuitry for determining a phase of the first signal after the first signal passes through the chiral solution, wherein the circuitry determines the phase by interfering the first signal having second orbital angular momentum signature therein with the first signal having plane waves therein.

6. The apparatus of claim 1, wherein the signal generation circuitry further comprises a hologram implemented with at least one of an amplitude mask, a phase mask, a spatial light modulator and a digital light processor.

7. The apparatus of claim 1, wherein the detector further comprises:

an orbital angular momentum detector for determining the detected second orbital angular momentum signature by taking the phase measurement and the amplitude measurement within the first signal from the chiral solution; and

a processor for determining a concentration of the amyloid-beta within the chiral solution responsive to the detected second orbital angular momentum signature.

8. The apparatus of claim 1, wherein differing signatures indicate different concentrations of the amyloid-beta within the chiral solution.

9. An apparatus for measuring a concentration of amyloid-beta within a chiral solution, comprising:

an emitting source for emitting a first signal comprising a plurality of plane waves;

orbital angular momentum generation circuitry for receiving the first signal and applying an orbital angular momentum signature to the first signal to provide an orbital angular momentum twisted signal;

a transmitter for applying the orbital angular momentum twisted signal to the chiral solution; and

a detector for receiving the orbital angular momentum twisted signal after the orbital angular momentum twisted signal passes through the chiral solution and determining the concentration of amyloid-beta within the chiral solution based on a detected second orbital angular momentum signature received caused by the chiral solution, wherein the detected second orbital angular momentum signature comprises an amplitude measurement and a phase measurement, wherein the detector further comprises;

an orbital angular momentum detector for determining the detected second orbital angular momentum signature by taking the phase measurement and the amplitude measurement within the first signal from the chiral solution; and

a processor for determining a concentration of the amyloid-beta within the chiral solution responsive to the detected second orbital angular momentum signature.

10. The apparatus of claim 9, wherein the detector negates effects of at least one of sample distribution due to gravity within the chiral solution, angle of camera recording a mode intensity to the chiral solution, a container holding the chiral solution, an angle of incidence of the first signal to the chiral solution and an angle exit of the first signal from the chiral solution to detect second orbital angular momentum signature.

11. The apparatus of claim 9, wherein the chiral solution is located in an eye of a patient.

12. The apparatus of claim 9, wherein the detector further includes circuitry for determining a phase of the first signal after the first signal passes through the chiral solution, wherein the circuitry determines the phase measurement by interfering the first signal having the second orbital angular momentum signature therein with the first signal having the plane waves therein.

13. The apparatus of claim 9, wherein the orbital angular momentum generation circuitry further comprises a hologram implemented with at least one of an amplitude mask, a phase mask, a spatial light modulator and a digital light processor.

14. The apparatus of claim 9, wherein differing signatures indicate different concentrations of the amyloid-beta within the chiral solution.

15. A method for detection an early onset of Alzheimer'"'"'s based upon amyloid beta concentration, comprising:

generating a first signal having an orbital angular momentum signature applied thereto;

applying the first signal to a chiral solution;

receiving the first signal after it passes through the chiral solution;

detecting a second orbital angular momentum signature within the received first signal, wherein the second orbital angular momentum signature comprises an amplitude measurement and a phase measurement;

determining a concentration of amyloid-beta within the chiral solution based on a detected second orbital angular momentum signature comprised of the amplitude measurement and the phase measurement within the first signal received from the chiral solution; and

determining if the concentration of amyloid-beta provides an indication of an early onset of Alzheimers.

16. The method of claim 15, wherein detecting further comprises negating effects of at least one of sample distribution due to gravity within the chiral solution, angle of camera recording a mode intensity to the chiral solution, a container holding the chiral solution, an angle of incidence of the first signal to the chiral solution and an angle exit of the first signal from the chiral solution to detect a change in an eccentricity of the mode intensity.

17. The method of claim 15, wherein the step of applying further comprises the step of applying the first signal to an eye of a patient in a non-intrusive manner.

18. The method of claim 15, wherein generating further comprises:

emitting the first signal comprising a plurality of plane waves; and

receiving the first signal; and

applying the orbital angular momentum signature to the first signal to provide an orbital angular momentum twisted signal.

19. The method of claim 15, wherein the determining the concentration further comprises:

interfering the first signal having the second orbital angular momentum signature therein with the first signal having plane waves therein; and

determining a phase of the first signal after the first signal passes through the chiral solution from the interfered first signal.

20. The method of claim 15, wherein the detecting further comprises determining the detected second orbital angular momentum signature by taking the phase measurement and the amplitude measurement within the first signal from the chiral solution.